ADvantage Therapeutics Welcomes Dr. Mark Hyman To Advisory Board To Advance Klothea Bio’s Klotho Longevity Initiatives

ADvantage Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for Alzheimer’s disease and other age-related conditions, has announced the appointment of Dr. Mark Hyman as a Scientific and Medical Advisor. Dr. Hyman will primarily focus on advancing ADvantage’s Klotho program through its wholly owned subsidiary, Klothea Bio, Inc., where he will serve on the Scientific Advisory Board. Klothea Bio is developing next-generation Klotho therapeutics and is preparing for its Phase 1B clinical trial, which will include assessments of Klotho’s effects on metabolic regulation.

Dr. Hyman is a globally recognized physician in longevity and aging science, an educator, and a New York Times bestselling author. His career spans clinical medicine and the biology of aging. He currently serves as Co-Founder and Chief Medical Officer of Function Health, Founder of the Cleveland Clinic Center for Functional Medicine, Chairman of the Food Fix Campaign, Founder and Director of The UltraWellness Center, and Board President for Clinical Affairs at the Institute for Functional Medicine. Additional information on Dr. Hyman is available at drhyman.com.

Expressing his enthusiasm, Dr. Hyman said, “I am particularly excited about the pioneering work being done on Klotho at Klothea Bio. The Klotho protein represents one of the most promising frontiers in aging science, and Klothea Bio is at the forefront of translating this science into therapies that may extend and improve human health span. I look forward to contributing to the advancement of this breakthrough research toward meaningful clinical impact.”

Jeffrey B. Madden, Chief Executive Officer of ADvantage Therapeutics and Executive Chair of Klothea Bio, commented, “Welcoming Dr. Mark Hyman to our team is an exceptional milestone. He is a world-renowned longevity physician, educator, and innovator whose expertise spans medicine, research, and public health. His guidance on aging biology and patient-focused care will be invaluable as we progress toward Phase 1B for our Klotho therapeutic.”

In addition to the Klotho program, ADvantage is preparing for a Phase 2B clinical trial of its lead candidate, AD04™, in Europe and the United Kingdom. The program has received fast track status under the Innovative Licensing and Access Pathway (ILAP). The company also recently announced an NIH grant supporting IND-enabling research for AD04™, further advancing its development pipeline.